Circulatory system

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

Retrieved on: 
Tuesday, February 20, 2024
Health, Medical Devices, Health Technology, General Health, Clinical Trials, Cardiology, Biotechnology, Volume overload, Pacyna, Diuretic, Physician, Acute decompensated heart failure, Leg, Standard of care, Heart failure, ADHF, FASTR, Reprieve, Fatigue, Patient, Medtronic, Circulatory system, Pharmaceutical industry

Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.

Key Points: 
  • Reprieve Cardiovascular , Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing.
  • The total round was co-led by Lightstone Ventures and Sante Ventures and joined by Deerfield Management, Genesis Capital, and Arboretum Ventures.
  • The funding will advance the Company’s clinical and development programs, including the ongoing FASTR trial and its upcoming pivotal trial.
  • Pacyna continued, “Reprieve Cardiovascular is bringing intelligent decongestion management to heart failure patients.

Connected Gym Equipment Market to grow by USD 4.23 billion from 2023-2028, North America to contribute 34% to the growth - Technavio

Retrieved on: 
Tuesday, February 6, 2024
Internet, Growth, Life Fitness, USD, Fitness, Challenge, Government, Nutrition, Commercial, Bowflex, Risk, Smartphone, Circulatory system, Health, Organization

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- The global connected gym equipment market size is estimated to grow by USD 4.23 billion from 2023 to 2028, according to Technavio.

Key Points: 
  • NEW YORK, Feb. 6, 2024 /PRNewswire/ -- The global connected gym equipment market size is estimated to grow by USD 4.23 billion from 2023 to 2028, according to Technavio.
  • North America, particularly the US, leads the connected gym equipment market, fueled by widespread smartphone adoption and internet penetration.
  • These factors contribute to the region's significant adoption of connected gym equipment, with continued growth expected in the forecast period.
  • Increasing smartphone penetration worldwide, along with the rising demand for connected gym services, are key drivers propelling the connected gym equipment market.

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Retrieved on: 
Friday, January 19, 2024
EON, RNA-Seq, Oligonucleotide, Knowledge, RNA, Science, Circulatory system, Mouse, NHP, NTCP, ACTB, Cholestasis, ANGPTL3, Cardiovascular disease, Plasma, Conference, B4GALT1, LDL, Liver, Eon, ProQR, ADAR, Nested polymerase chain reaction, CNS, Video game

“We were pleased to present new in vivo data for our proprietary Axiomer RNA editing technology platform at the Deaminet 2024 meeting, demonstrating robust editing of ACTB in the liver of NHP, as well as functional protein data with the liver target ANGPTL3 in mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR.

Key Points: 
  • “We were pleased to present new in vivo data for our proprietary Axiomer RNA editing technology platform at the Deaminet 2024 meeting, demonstrating robust editing of ACTB in the liver of NHP, as well as functional protein data with the liver target ANGPTL3 in mice,” said Gerard Platenburg, Chief Scientific Officer of ProQR.
  • “To date, we have generated robust in vitro and in vivo preclinical platform data across a range of liver and CNS targets.
  • Presentation of new data highlighting up to 70% editing efficiency of ACTB in liver of mice and NHPs at multiple timepoints.
  • These new preclinical platform data further highlight the potential of Axiomer EONs in preparation for clinical development and supporting discovery of potential new therapeutic applications.

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

Retrieved on: 
Wednesday, January 17, 2024
Mortality, Death, Patient, Incidence, ICU, Cytokine adsorbing column, Vasoplegic syndrome, Semmelweis University, Professional corporation, DRS, European Society of Cardiology, RCT, Heart, Standard of care, Pelvic floor dysfunction, Cytosorbents Corporation, Circulatory system, Risk, Organ dysfunction, VS, Multiple organ dysfunction syndrome, Observational study, Shock, Randomized controlled trial, ESC, Dentistry

In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.

Key Points: 
  • In particular, vasoplegic syndrome (VS), a form of circulatory failure or shock, is routinely seen in these patients and can cause worsened organ failure.
  • In a prior observational study , CytoSorb was associated with the reduced severity of vasoplegia in heart transplant patients, in addition to other clinical benefits.
  • In this prospective, single-center, open-label RCT, 60 heart transplant recipients were randomly assigned to either receive intraoperative CytoSorb hemoadsorption or standard of care.
  • Now, Nemeth, Soltesz, and colleagues have confirmed many of these observations in this rigorous and well-designed groundbreaking randomized controlled trial in orthotopic heart transplant patients.

The Inner Circle Acknowledges, Divyakant B. Gandhi, MBBS, FRCS, FACS as a Distinguished Cardiothoracic Surgeon

Retrieved on: 
Monday, January 15, 2024
Student, Atrial fibrillation, Patient, University, Research, Medical college, FRCS, Health, Multimedia, Heart, Inner circle, Cardiothoracic surgery, Circulatory system, FACS, Royal, Elective surgery, Coronary artery disease, Medicine, Mentorship, General surgery, Lung cancer, Ohio State University, Quality of life, Royal college, Georgia Tech, American College, Intellectual property, Ventricular septal defect, McLaren Health Care Corporation, Parent, Doctor of Philosophy, Multiple, Education, Mitral valve, Lung, MBBS, Physician

Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.

Key Points: 
  • Divyakant B. Gandhi is an international physician, innovative thinker, and leader in cardiac care.
  • He has been in practice as a Heart, Lung & Vascular surgeon for over 35 years.
  • As a leader in the clinical setting, Dr. Gandhi is the Chief of Staff, Medical Director, and Chief of Cardiovascular & Thoracic Surgery at McLaren Greater Lansing.
  • Dr. Gandhi practices his specialty under the auspices of the Center for Cardiovascular and Thoracic Surgery in Detroit, MI.

Global Atherectomy Devices Market Report 2023-2030: Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, January 8, 2024
Health, Medical Devices, Cardiology, Artery, Heart, Statistics, Neurovascular bundle, Cardinal Health, Circulatory system, Atherectomy, World Health Organization, Stroke, Prevalence, Atherosclerosis, Abbott Laboratories, Physician, CAD, Blood, Myocardial infarction, Patient, Australian Bureau of Statistics, Acute coronary syndrome, Incidence, Element, Plaque, World Games, Application, PAD, Pharmaceutical industry

The "Atherectomy Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atherectomy Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Atherectomy devices are minimally invasive medical devices that are used to eliminate plaque build-up from the partitions of arteries.
  • By Product Type, Global Atherectomy Devices Market is divided into Directional Atherectomy, Rotational Atherectomy, Orbital Atherectomy and Laser Atherectomy.
  • Hospitals are poised to maintain their stronghold with the very best market proportion in the Atherectomy Devices Market.

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Circulatory system, FDA, Marketing, Quality control, Rifampicin, Partnership, Growth, Minocycline, Rare-earth element, Airline, Medical device, Pharmaceutical industry, Video game

SILVER SPRING, Md., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Successfully completed transformation to Elutia, establishing a high growth company dedicated to developing and marketing propriety drug eluting biomatrices.
  • Achieved a significant 44% year-over-year increase in SimpliDerm® net sales and an 11% year-over-year growth in CanGaroo® net sales.
  • Net sales for the third quarter of 2023 were $6.1 million, compared to $5.8 million in the third quarter of 2022.
  • Elutia will host a conference call today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its third quarter 2023 financial results and performance.

Closure Devices Lead Sternal Closure Systems Market: Innovations in Surgical Techniques Boost Adoption - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023
Surgery, Health, Prevalence, Circulatory system, Patient, Cardiovascular disease, Heart failure, Coronary artery disease, Compound annual growth rate, Sternum, Vascular closure device, Ageing, Trauma, Growth, Video-assisted thoracoscopic surgery, Video game, Dentistry, Health insurance

These systems play a vital role in the closure and stabilization of the sternum following open-heart surgery or sternotomy.

Key Points: 
  • These systems play a vital role in the closure and stabilization of the sternum following open-heart surgery or sternotomy.
  • As these diseases become more common, there is a rising demand for sternal closure systems.
  • Advancements in Surgical Techniques: Innovations in surgical techniques, including minimally invasive cardiac surgeries, have led to a growing need for specialized sternal closure systems that offer stability, reduced trauma, and enhanced patient outcomes.
  • Closure Devices Dominate the Market: Closure devices, including rigid plate systems, wire cerclage systems, and interlocking systems, generated the highest revenue in the sternal closure systems market in 2022.

NorthShore - Edward-Elmhurst Health is Now Endeavor Health

Retrieved on: 
Tuesday, December 5, 2023
Magnet, Orthopedic surgery, Research, Primary care, Circulatory system, FAQ, Patient, North Star Bicycle Festival, Trust, Health, Swedish Hospital, Neuroscience, NorthShore University HealthSystem, North, Hospital, Physician, Name, Nursing, Cancer

EVANSTON, Ill., Dec. 5, 2023 /PRNewswire/ -- NorthShore – Edward-Elmhurst Health today revealed the name and unified brand for its newly combined health system: Endeavor Health℠.

Key Points: 
  • EVANSTON, Ill., Dec. 5, 2023 /PRNewswire/ -- NorthShore – Edward-Elmhurst Health today revealed the name and unified brand for its newly combined health system: Endeavor Health℠.
  • This announcement marks an exciting milestone following the merger between NorthShore University HealthSystem (NorthShore), including Swedish Hospital and Northwest Community Healthcare and Edward-Elmhurst Health, creating the third largest health system in Illinois serving an area of 4.2 million residents.
  • "Both inspirational and aspirational, Endeavor Health embodies our mission to help everyone in our communities be their best," said J.P. Gallagher, President and Chief Executive Officer, Endeavor Health.
  • Advancing the health, wellbeing and economic security of the communities it serves will be an enduring focus for Endeavor Health.

IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights

Retrieved on: 
Wednesday, November 15, 2023
Lung, Woman, CIRSE, Freezing, Patient, Participation, Research, Kidney, Marketing, Neoplasm, Conference, Congress, System, ICE3, Hamas, Webcast, Safety, Food, Luminate (company), European Society of Radiology, Conference call, ANVISA, Health, Breast, Cryoablation, Breast cancer, Kidney cancer, Nine Months, Classification, Brazilian Health Regulatory Agency, Prostate, Health Canada, De novo, Circulatory system, Liver, Novomer, Episcopal conference, FDA, Cancer Diagnostic Probe, Medical device, Pharmaceutical industry, Nursing, Medical imaging, Birth control, Cryptocurrency, Broadcasting, Luminal

Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.

Key Points: 
  • Gross profit was $0.73 million for the nine months ended September 30, 2023, compared to $0.98 million for the nine months ended September 30, 2022.
  • Gross margin was 37% for the nine months ended September 30, 2023, compared to 46% for the nine months ended September 30, 2022.
  • Research and development expenses for the nine months ended September 30, 2023, were $6.39 million compared to $6.89 million for the nine months ended September 30, 2022.
  • Total operating expenses for the nine months ended September 30, 2023, were $12.89 million, compared to $13.79 million for the nine months ended September 30, 2022.